drugset / Trial / NCT00446329
Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The 1st phase of the study will assess the acute biochemical response of PTH, calcium and phosphorus to orally administered doses of cinacalcet once (60mg) or twice (30mg x 2) per day. The 2nd phase of the study designed to evaluate the long term effects of cinacalcet on BMD (bone mineral density)and the levels of PTH, calcium, phosphorus as well as its ability to control secondary hyperparathyroidism without simultaneous administration of other vitamin D compounds.
Timeline
- Start
- 2006-07
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cinacalcet | Other / unclassified | 30 mg | Oral |
| Subject | Cinacalcet | Other / unclassified | 60 mg | Oral |
| Subject | Cinacalcet | Other / unclassified | 180 mg | Oral |